The underlying pathology of Alzheimer’s disease (AD) is complex and includes, besides amyloid beta (Aβ) plaque depositions and neurofibrillary tangles, brain atrophy and neurodegeneration, neuroinflammation, impaired neurogenesis, vascular and blood–brain barrier (BBB) disruptions, neurotransmitter disbalances, and others. Here, we hypothesize that such complex pathologies can only be targeted efficiently through pleiotropic approaches. One interesting drug target is the leukotriene pathway, which mediates various aspects of AD pathology. Approaching this pathway at different levels with genetic and pharmacological tools demonstrated beneficial outcomes in several in vivo studies using different mouse models of AD. Here, we review the current literature on the leukotriene signaling pathway as a target for drug development in AD.

阿尔茨海默氏病（AD）的潜在病理学很复杂，除了淀粉样蛋白（Aβ）斑块沉积和神经原纤维缠结之外，还包括脑萎缩和神经退行性病变，神经炎症，神经发生受损，血管和血脑屏障（BBB）破坏，神经递质失衡，和别的。在这里，我们假设只能通过多效性方法有效地靶向这类复杂的病理学。一种有趣的药物靶标是白三烯途径，其介导AD病理学的各个方面。使用遗传和药理学工具在不同水平上探索该途径证明了几种体内有益的结果使用不同的AD鼠标模型进行研究。在这里，我们回顾了有关白三烯信号通路作为AD中药物开发目标的最新文献。